


FlexTouch® incl. API and needle

product carbon footprint

version 3.1



1. Background

Novo Nordisk analyses and understands carbon emissions at the product level. This document presents the Product Carbon Footprint of one year treatment with FlexTouch® in combination with a range of APIs, including the use of NovoFine® needle, hereafter referred to as the [API brand name] FlexTouch® carbon footprint¹, e.g. Tresiba® FlexTouch® carbon footprint.

Full carbon footprint reports for the APIs, device and needle are available.

The data presented in this document supports marketing claims and Q&As about the product carbon footprint. The data should not be used for comparison with competitor products or for claims related to 'green' or 'environmentally friendly' products.

2. Product carbon footprint methodology

The carbon footprint of a product is calculated by adding the greenhouse gas emissions (in kg CO₂ equivalents) from different stages of the product lifecycle as shown in the figure below. The product carbon footprint of one year treatment is calculated by adding the contributions from the active pharmaceutical ingredient (API), the device and the needle².



The Novo Nordisk carbon footprint calculations follow the Greenhouse Gas Accounting Sector Guidance for Pharmaceutical Products and Medical Devices³, which is built on international life cycle assessment standards. The reports are third-party reviewed by PricewaterhouseCoopers Advisory.

The carbon footprint calculations are based on production data from 2019 (except waste which is based on 2015 production data) and cover use at three major markets: Europe, US and Japan. The calculations are made using Excel and the life cycle assessment tool GaBi.

The [API brand name] FlexTouch® carbon footprint consists of three elements: API, device and needle. The key assumptions for each of these elements are given below.

¹ In the case of Xultophy® and Saxenda® it is the 'Xultophy® / Saxenda® carbon footprint' as the brand name covers both the API and the device.

² Including the packaging for devices and needles.

³ Greenhouse Gas Accounting Sector Guidance for Pharmaceutical Products and Medical Devices, GHG Protocol Product Life Cycle Accounting and Reporting Standard, November 2012. At: http://ghgprotocol.org/sites/default/files/ghgp/Summary-Document_Pharmaceutical-Product-and-Medical-Device-GHG-Accounting_November-2012_0.pdf. Accessed May 2021

- **API:** The daily dose is 40 units of insulin, which corresponds to the WHO guidelines⁴ for defined daily dose (DDD). The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The average daily dose of Xultophy® is 1.44 mg liraglutide and 40 units of insulin degludec per day. The average daily dose of Saxenda® is 3 mg liraglutide. The weekly dose of Ozempic® is 0.5 mg or 1.0 mg.
- **Device:** FlexTouch® with a U100 cartridge contains 300 units of insulin. FlexTouch® with a U200 cartridge contains 600 units of insulin. When used with liraglutide, a 3 ml cartridge contains 18 mg of active ingredient, when used with semaglutide, a 1.5 ml cartridge contains 2 mg of active ingredient and a 3.0 ml cartridge contains 4 mg.
- **Needle:** Novo Nordisk recommends discarding of the needle after use. However, market research shows that most patients use the needle several times⁵. To reflect an average patient, the one year treatment scenario is based on the use of one needle per day, which can be considered a conservative estimate.

3. Product carbon footprint of one year treatment

The [API brand name] FlexTouch® carbon footprint for insulin products is 8-24 kg of CO₂ equivalents per year, corresponding to 22-65 g of CO₂ equivalents per day. For the combination of insulin and GLP-1, Xultophy®, the carbon footprint is 16-24 kg of CO₂ equivalents per year, corresponding to 44-66 g of CO₂ equivalents per day. For Ozempic®, the carbon footprint is 3-6 kg of CO₂ equivalents per year, corresponding to 8-15 g of CO₂ equivalents per day. For Saxenda®, the carbon footprint is 21-31 kg of CO₂ equivalents per year, corresponding to 57-84 g of CO₂ equivalents per day. The results for each of the APIs and country scenarios are included in Appendix A.

To put this into perspective for a non-expert, it is possible to compare the carbon footprint to other consumables.

One year insulin treatment with [API brand name] FlexTouch® corresponds to driving 68-200 km in an average new car in Europe. For Xultophy®, one year treatment corresponds to driving 135-202 km in an average new car in Europe. For Ozempic®, one year treatment corresponds to driving 25-47 km in an average new car in Europe. For Saxenda®, one year treatment corresponds to driving 176-260 km in an average new car in Europe. The CO₂ emissions per km data is based on an EU-28 average published by Eurostat⁶.

It is estimated that the daily environmental impact (using carbon footprint as proxy) of diabetes treatment using [API brand name] FlexTouch® is equivalent to a cup of tea⁷. According to Cichorowski et al. (2015), the cradle to grave carbon footprint of Darjeeling tea including cultivation and brewing is 0.15 kg of CO₂ equivalents per litre

⁴ WHO Collaborating Centre for Drug Statistics Methodology (WHOC): DDD Definition and general considerations. http://www.whocc.no/ddd/definition_and_general_considera/. Accessed Sep 2021.

⁵ Roper U.S. Diabetes 2014 Patient Study. Insulin devices market. GfK, November 2014

⁶ Eurostat (2019). Average carbon dioxide emissions per km from new passenger cars, http://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=t2020_rk330&plugin=1. Accessed Sep 2021.

⁷ This is not the case for Levemir®, Xultophy® and Saxenda® for the Japanese market.

of tea⁸. A 40 cl cup of tea will thus have a carbon footprint of 60 g of CO₂ equivalents. It must be acknowledged that “a cup of tea” is an ambiguous measure and there are many different types of tea and brewing methods, but the calculation gives a good indication of the size of the impacts related to treatment of diabetes.

A comparison with air travel shows that the carbon footprint of 13-39 years of treatment with [API brand name] FlexTouch® corresponds to a flight from London to New York. For Xultophy®, the carbon footprint of 13-19 years of treatment corresponds to a flight from London to New York, for Ozempic®, the carbon footprint of 55-107 years of treatment corresponds to a flight from London to New York and for Saxenda®, the carbon footprint of 10-15 years of treatment corresponds to a flight from London to New York. This is calculated on the basis of data from the ICAO Carbon Emissions Calculator⁹.

The carbon footprint has inherent uncertainties and should be regarded as an indicative level and not as a precise measure. The uncertainties relate to the data collected from Novo Nordisk production, the data on carbon footprint for each of the processes (e.g. plastic granulate production), carbon footprint impact factors and the key assumptions (e.g. distribution patterns). Moreover, the calculations take into account that Novo Nordisk sources renewable energy through certificates, which results in a lower carbon footprint than if average electricity was used.

The plastic footprint¹⁰ of one year treatment with NovoRapid®, Fiasp®, Tresiba® U100, Levemir®, Ryzodeg® and Xultophy® in FlexTouch® including needles is 0.96 kg plastic per patient per year.

The plastic footprint of one year treatment with Tresiba® U200 in FlexTouch® including needles is 0.51 kg plastic per patient per year.

The plastic footprint of one year treatment with Saxenda® in FlexTouch® including needles is 1.19 kg plastic per patient per year.

The plastic footprint of one year treatment with Ozempic® in FlexTouch® including needles is 0.25 kg plastic per patient per year.

4. Reducing the product carbon footprint

Novo Nordisk strives to reduce carbon footprint throughout the product lifecycle, and [API brand name] FlexTouch® is produced with the environment in mind.

Our environmental strategy, Circular for Zero, and the certified ISO14001 Environmental Management System drive continuous improvements of our environmental performance by setting high ambitions and integrating environmental considerations into daily business activities. Moreover, life cycle assessment is an integrated part of our device product development process.

⁸ Cichorowski et al. (2015). Scenario analysis of life cycle greenhouse gas emissions of Darjeeling tea. *Int J Life Cycle Assess* (2015) 20:426–439

⁹ ICAO (International Civil Aviation Organization) (June 2018). Carbon Emissions Calculator. <http://www.icao.int/environmental-protection/CarbonOffset/Pages/default.aspx>. Accessed Sep 2021.

¹⁰ Calculated as the plastic contained in the pens and the needles used in the yearly treatment, excluding any packaging material.

Novo Nordisk is using 100% renewable electricity at all production sites¹¹.

¹¹ Novo Nordisk Annual Report 2020, p.12 - https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2021/Novo-Nordisk-Annual-Report-2020.pdf

5. Appendix A: Product carbon footprint results and comparisons

Table 1. Carbon footprint of treatment at the European market

Brand name	Carbon footprint of API device incl. cartridge [kg CO ₂ -eq.]	Carbon footprint of cartridge [kg CO ₂ -eq.]	Carbon footprint of needle [kg CO ₂ -eq.]	Carbon footprint of one year treatment [kg CO ₂ -eq.]	Carbon footprint of daily treatment [g CO ₂ -eq.]
NovoRapid® FlexTouch®	1.0	7.1	2.9	11	30
Fiasp® FlexTouch®	1.0	7.1	2.9	11	30
Tresiba® FlexTouch® U100	1.6	7.1	2.9	12	32
Tresiba® FlexTouch® U200	1.6	3.5	2.9	8	22
Levemir® FlexTouch®	5.7	7.1	2.9	16	43
Ryzodeg® FlexTouch®	1.4	7.1	2.9	11	31
Xultophy®	6.0	7.1	2.9	16	44
Saxenda®	9.1	8.8	2.9	21	57
Ozempic® 0.5mg	0.6	1.9	0.4	3	8
Ozempic® 1.0mg	1.2	1.9	0.4	4	10

Table 2. Carbon footprint of treatment at the US market

Brand name	Carbon footprint of API device incl. cartridge [kg CO ₂ -eq.]	Carbon footprint of cartridge [kg CO ₂ -eq.]	Carbon footprint of needle [kg CO ₂ -eq.]	Carbon footprint of one year treatment [kg CO ₂ -eq.]	Carbon footprint of daily treatment [g CO ₂ -eq.]
NovoRapid® FlexTouch®	1.0	8.0	2.6	12	32
Fiasp® FlexTouch®	1.0	8.0	2.6	12	32
Tresiba® FlexTouch® U100	1.6	8.0	2.6	12	34
Tresiba® FlexTouch® U200	1.6	4.0	2.6	8	23
Levemir® FlexTouch®	5.7	8.0	2.6	16	45
Ryzodeg® FlexTouch®	1.4	8.0	2.6	12	33
Xultophy®	6.0	8.0	2.6	17	46
Saxenda®	9.1	10.0	2.6	22	60
Ozempic® 0.5mg	0.6	2.1	0.4	3	9
Ozempic® 1.0mg	1.2	2.1	0.4	4	10

Table 3. Carbon footprint of treatment at the Japanese market

Brand name	Carbon footprint of API device incl. cartridge [kg CO ₂ -eq.]	Carbon footprint of needle [kg CO ₂ -eq.]	Carbon footprint of one year treatment [kg CO ₂ -eq.]	Carbon footprint of daily treatment [g CO ₂ -eq.]
NovoRapid® FlexTouch®	1.0	14.7	3.2	19
Fiasp® FlexTouch®	1.0	14.7	3.2	19
Tresiba® FlexTouch® U100	1.6	14.7	3.2	20
Tresiba® FlexTouch® U200	1.6	7.4	3.2	12
Levemir® FlexTouch®	5.7	14.7	3.2	24
Ryzodeg® FlexTouch®	1.4	14.7	3.2	19
Xultophy®	6.0	14.7	3.2	24
Saxenda®	9.1	18.4	3.2	31
Ozempic® 0.5mg	0.6	3.9	0.5	5
Ozempic® 1.0mg	1.2	3.9	0.5	6

Table 4. Comparison with driving a car. Number of km travelled in an average new car.

Brand name	EU	US	JP
NovoRapid® FlexTouch®	93	99	160
Fiasp® FlexTouch®	93	99	160
Tresiba® FlexTouch® U100	98	103	165
Tresiba® FlexTouch® U200	68	70	103
Levemir® FlexTouch®	133	138	200
Ryzodeg® FlexTouch®	96	102	163
Xultophy®	135	140	202
Saxenda®	176	184	260
Ozempic® 0.5mg	25	26	42
Ozempic® 1.0mg	30	31	47

Table 5. . Comparison with air travel. Years of use corresponding to a flight from London to New York

Brand name	EU	US	JP
NovoRapid® FlexTouch®	28	27	16
Fiasp® FlexTouch®	28	27	16
Tresiba® FlexTouch® U100	27	25	16
Tresiba® FlexTouch® U200	39	38	26
Levemir® FlexTouch®	20	19	13
Ryzodeg® FlexTouch®	27	26	16
Xultophy®	19	19	13
Saxenda®	15	14	10
Ozempic® 0.5mg	107	100	62
Ozempic® 1.0mg	88	83	55

References

Aspart carbon footprint, Novo Nordisk, Sep 2021
 Degludec carbon footprint, Novo Nordisk, Sep 2021
 Detemir carbon footprint, Novo Nordisk, Sep 2021
 Liraglutide carbon footprint, Novo Nordisk, Sep 2021
 Human insulin carbon footprint, Novo Nordisk, Sep 2021
 FlexTouch® carbon footprint, Novo Nordisk, Sep 2021
 NovoFine® carbon footprint, Novo Nordisk, Sep 2021
 Semaglutide carbon footprint, Novo Nordisk, Sep 2021



Third party verification of Novo Nordisk Carbon Footprint reports

Novo Nordisk A/S

Novo Allé 1
DK-2880 Bagsværd
Denmark

Novo Nordisk has commissioned PricewaterhouseCoopers Advisory (PwC) to review several carbon footprint reports for diabetes products prepared by Novo Nordisk. The critical review (CR) was done according to the ISO/TS 14 071¹, ISO 14 040², ISO 14 044³ recommendations and also according to the “Greenhouse Gas Accounting Sector Guidance for Pharmaceutical Products and Medical Devices” recommendations. The CR expert is independent from Novo Nordisk and was not involved in the making of the study. To ensure consistency with the principles and requirements of the standards and guidance (ISO/TS 14 071, ISO 14 040, ISO 14 044, and Greenhouse Gas Accounting Sector Guidance for Pharmaceutical Products and Medical Devices) on life cycle assessment, the CR was performed by the following LCA expert of PwC: Christophe Drevelle.

The CR of the study appraises the following:

- the methods used are consistent with the standards ISO 14040 and 14044 and Greenhouse Gas Accounting Sector Guidance for Pharmaceutical Products and Medical Devices;
- the methods used are scientifically and technically valid;
- the data used are appropriate and reasonable in relation to the goal and scope of the study;
- the interpretation reflects the limitations identified and the goal of the study;
- the report is transparent and consistent.

During this period, different oral and written exchanges have been held between PwC and Novo Nordisk, including clarification exchanges regarding the CR comments, and the production of new versions of the carbon footprint reports by Novo Nordisk. Novo Nordisk has taken into account all the comments and has modified and improved its report.

The 2020/2021 study is in conformity with the standards ISO 14040 and 14044 and Greenhouse Gas Accounting Sector Guidance for Pharmaceutical Products and Medical Devices.

Note: this is an extraction of full version of verification report from PWC. The more detailed verification report is available.

A handwritten signature in blue ink, appearing to read 'Sylvain Lambert', is positioned above the printed name.

Neuilly-sur-Seine (France), December 22nd, 2021

Sylvain Lambert
Partner of Sustainable Development Department

¹ ISO/TS 14071 (2014): Environmental management -- Life cycle assessment -- Critical review processes and reviewer competencies: Additional requirements and guidelines to ISO 14044 (2006)

² ISO 14040 (2006): Environmental management -- Life cycle assessment -- Principles and framework

³ ISO 14044 (2006): Environmental management -- Life cycle assessment -- Requirements and guidelines